Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER project
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Purpose Next-generation sequencing (NGS) can facilitate precision medicine approaches in metastatic colorectal cancer (mCRC) patients. We investigated the molecular profiling of Korean mCRC patients under the K-MASTER project which was initiated in June 2017 as a nationwide precision medicine oncology clinical trial platform which used NGS assay to screen actionable mutations. Materials and Methods As of 22 January 2020, total of 994 mCRC patients were registered in K-MASTER project. Targeted sequencing was performed using three platforms which were composed of the K-MASTER cancer panel v1.1 and the SNUH FIRST Cancer Panel v3.01. If tumor tissue was not available, cell-free DNA was extracted and the targeted sequencing was performed by Axen Cancer Panel as a liquid biopsy. Results In 994 mCRC patients, we found 1,564 clinically meaningful pathogenic variants which mutated in 71 genes. Anti-EGFR therapy candidates were 467 patients (47.0%) and BRAF V600E mutation (n=47, 4.7%), deficient mismatch repair/microsatellite instability–high (n=15, 1.5%), HER2 amplifications (n=10, 1.0%) could be incorporated with recently approved drugs. The patients with high tumor mutation burden (n=101, 12.7%) and DNA damaging response and repair defect pathway alteration (n=42, 4.2%) could be enrolled clinical trials with immune checkpoint inhibitors. There were more colorectal cancer molecular alterations such as PIK3CA, KRAS G12C, atypical BRAF, and HER2 mutations and even rarer but actionable genes that approved or ongoing clinical trials in other solid tumors. Conclusion K-MASTER project provides an intriguing background to investigate new clinical trials with biomarkers and give therapeutic opportunity for mCRC patients.
Abstract
Purpose Next-generation sequencing (NGS) can facilitate precision medicine approaches in metastatic colorectal cancer (mCRC) patients. We investigated the molecular profiling of Korean mCRC patients under the K-MASTER project which was initiated in June 2017 as a nationwide precision medicine oncology clinical trial platform which used NGS assay to screen actionable mutations. Materials and Methods As of 22 January 2020, total of 994 mCRC patients were registered in K-MASTER project. Targeted sequencing was performed using three platforms which were composed of the K-MASTER cancer panel v1.1 and the SNUH FIRST Cancer Panel v3.01. If tumor tissue was not available, cell-free DNA was extracted and the targeted sequencing was performed by Axen Cancer Panel as a liquid biopsy. Results In 994 mCRC patients, we found 1,564 clinically meaningful pathogenic variants which mutated in 71 genes. Anti-EGFR therapy candidates were 467 patients (47.0%) and BRAF V600E mutation (n=47, 4.7%), deficient mismatch repair/microsatellite instability–high (n=15, 1.5%), HER2 amplifications (n=10, 1.0%) could be incorporated with recently approved drugs. The patients with high tumor mutation burden (n=101, 12.7%) and DNA damaging response and repair defect pathway alteration (n=42, 4.2%) could be enrolled clinical trials with immune checkpoint inhibitors. There were more colorectal cancer molecular alterations such as PIK3CA, KRAS G12C, atypical BRAF, and HER2 mutations and even rarer but actionable genes that approved or ongoing clinical trials in other solid tumors. Conclusion K-MASTER project provides an intriguing background to investigate new clinical trials with biomarkers and give therapeutic opportunity for mCRC patients.
참고문헌 (26)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016", Cancer Research and Treatment, 51(2), pp.417~430 (2019), 대한암학회
- 최정윤, "Clinical Implication of Concordant or Discordant Genomic Profiling Between Primary and Matched Metastatic Tissues in Patients with Colorectal Cancer", Cancer Research and Treatment, 52(3), pp.764~778 (2020), 대한암학회[DOI]
- Cancer Genome Atlas Network, "Comprehensive molecular characterization of human colon and rectal cancer", Nature, 487, pp.330~337 (2012)
- Shin HT, "Prevalence and detection of low-allele-fraction variants in clinical cancer samples", Nat Commun, 8, pp.1377~ (2017)
- Cunningham D, "Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer", N Engl J Med, 351, pp.337~345 (2004)
- Van Cutsem E, "Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer", N Engl J Med, 360, pp.1408~1417 (2009)
- Kim SY, "Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer", ESMO Open, 5, pp.e000634~ (2020)
- Kopetz S, "Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer", N Engl J Med, 381, pp.1632~1643 (2019)
- Meric-Bernstam F, "Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer(MyPathway) : an updated report from a multicentre, open-label, phase 2a, multiple basket study", Lancet Oncol, 20, pp.518~530 (2019)
- Sartore-Bianchi A, "Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12", 13 wild-type, HER2-positive metastatic colorectal cancer(HERACLES) : a proof-of-concept, multicentre, open-label, phase 2 trial, 2016, pp.17, 738~746
- Le DT, "PD-1 blockade in tumors with mismatch-repair deficiency", N Engl J Med, 372, pp.2509~2520 (2015)
- Overman MJ, "Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer(CheckMate 142) : an open-label, multicentre, phase 2 study", Lancet Oncol, 18, pp.1182~1191 (2017)
- Overman MJ, "Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient", mcrosatellite instability-high metastatic colorectal cancer, 2018, pp.36, 773~779
- Mouw KW, "DNA damage and repair biomarkers of immunotherapy Response", Cancer Discov, 7, pp.675~693 (2017)
- Chalmers ZR, "Analysis of 100, 000 human cancer genomes reveals the landscape of tumor mutational burden", Genome Med, 9, pp.34~ (2017)
- Lee DW, "Tumor mutation burden and prognosis in patients with colorectal cancer treated with adjuvant fluoropyrimidine and oxaliplatin", Clin Cancer Res, 25, pp.6141~6147 (2019)
- Pietrantonio F, "ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer", J Natl Cancer Inst, 109, pp.djx089~ (2017)
- Gautschi O, "Targeting RET in patients with RET-rearranged lung cancers : results from the global, multicenter RET registry", J Clin Oncol, 35, pp.1403~1410 (2017)
- Drilon A, "Efficacy of larotrectinib in TRK fusionpositive cancers in adults and children", N Engl J Med, 378, pp.731~739 (2018)
- Drilon A, "Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib : combined results from two phase I trials(ALKA-372-001 and STARTRK-1)", Cancer Discov, 7, pp.400~409 (2017)
- Dos Santos W, "Mutation profiling of cancer drivers in Brazilian colorectal cancer", Sci Rep, 9, pp.13687~ (2019)
- D’Haene N, "Clinical application of targeted next-generation sequencing for colorectal cancer patients : a multicentric Belgian experience", Oncotarget, 9, pp.20761~20768 (2018)
- Salem ME, "Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers", Oncotarget, 8, pp.86356~86368 (2017)
- Giannakis M, "Genomic correlates of immune-cell infiltrates in colorectal carcinoma", Cell Rep, 17, pp.1206~ (2016)
- Zhang J, "International Cancer Genome Consortium Data Portal: a one-stop shop for cancer genomics data", Database (Oxford), 2011, pp.bar026~ (2011)
- Dong Z, "Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients", Sci Rep, 9, pp.16894~ (2019)